Intuitive Surgical stock (US46120E6023): Citi keeps buy call as shares trade near 52-week low

Intuitive Surgical traded at $418.55 on 05/28/2026 in U.S. trading, while Citi kept a Buy rating and a $590 target. The stock also remains active on Nasdaq and in the U.S. market as investors weigh valuation against fresh analyst coverage.

Intuitive Surgical shares were last quoted at $418.55 on 05/28/2026, and Citi kept a Buy rating with a $590 price target, according to market data and a recent analyst note. The move gives U.S. investors a fresh read on the Nasdaq-listed medtech name as it trades well below its 52-week high of $603.70 and near the lower end of its yearly range, based on quoted data from the U.S. market and the latest third-party coverage.

The stock's latest trade on the U.S. market came alongside a 52-week low of $414.58 and a 52-week high of $603.70, underscoring how much sentiment has shifted since earlier in the year. In home-country terms, Intuitive Surgical remains a U.S.-listed company on Nasdaq, and that primary listing is the key reference point for traders following the name from the United States.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Intuitive Surgical
• Sector/industry: Medical technology, robotic-assisted surgical systems
• Headquarters/country: Sunnyvale, United States
• Core markets: United States and other international hospital markets
• Key revenue drivers: da Vinci system placements, instruments and accessories, and service contracts
• Home exchange/listing venue: Nasdaq (ISRG)
• Trading currency: USD

Intuitive Surgical: core business model

Intuitive Surgical develops and services robotic-assisted surgical systems, with its da Vinci platform at the center of the franchise, and it monetizes the installed base through recurring instruments, accessories, and service revenue.

Valuation metrics and multiples for Intuitive Surgical

On 05/28/2026, Moneycontrol showed Intuitive Surgical at a previous close of $418.55, a high of $424.81, a low of $414.75, and a 52-week range of $414.58 to $603.70, while also listing a TTM EPS trend of 9.62. MarketBeat reported on 05/28/2026 that Citi's Joanne Wuensch maintained a Buy rating and a $590 target, and that Baird had increased its target from $575 to $610 while keeping an Outperform stance.

That combination places valuation squarely at the center of the debate for U.S. investors watching Nasdaq-listed health care stocks. MarketBeat also said the consensus across analysts it tracks is Moderate Buy with an average target of $576.71 as of 05/28/2026, which gives the latest price action a clear benchmark without changing the fact that the stock is still sensitive to any update on earnings, margins, or procedure growth.

Conclusion

The latest U.S. session leaves Intuitive Surgical framed less by corporate action and more by valuation, with Citi's maintained Buy call and a $590 target offering one current reference point for Nasdaq traders. For Friday's module, the key takeaway is that the stock's range remains wide enough to keep analyst targets, recent closes, and the 52-week band in focus.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.